Adding a gut bacteria treatment to cancer immunotherapy after kidney surgery

Plain-English translation of NCT07037004 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether adding a live bacterial supplement called CBM588 to —a standard immunotherapy drug—can help people with high-risk kidney cancer stay cancer-free longer after surgery. The study will compare patients who receive both the supplement and the immunotherapy drug with patients who receive the immunotherapy drug alone. Researchers believe the bacterial supplement may help boost the body's immune response to fight any remaining cancer cells.

Even after surgery to remove a kidney tumor, cancer can sometimes return because microscopic cancer cells may remain in the body. This medication works to help the immune system find and destroy those cells, but researchers want to know if adding the bacterial supplement can make this treatment work even better by enhancing the immune response.

Do you qualify?

You likely qualify if…

you have been diagnosed with kidney cancer (clear-cell or sarcomatoid types) and had surgery to remove it
your cancer is considered high-risk (certain stages) but shows no signs of disease after surgery, or you have a small amount of residual disease
you have not received any prior immunotherapy drugs for kidney cancer
you are at least 18 years old and in generally good health (able to care for yourself with minimal assistance)
your kidney and liver function test results are acceptable, and your blood cell counts are adequate

You likely don't qualify if…

you have a history of autoimmune disease or have recently taken high-dose steroids or immune-suppressing medications
you have active lung inflammation or a history of lung inflammation that required steroid treatment
you are currently taking probiotics, prebiotics, yogurt with added bacteria, or similar supplements within 2 weeks before starting the study
you have uncontrolled adrenal insufficiency or certain conditions that cause chronic diarrhea
you have received prior radiation therapy or other immunotherapy drugs (anti-PD1, anti-PDL1, or anti-CTLA-4) for kidney cancer

What participation looks like

You will be randomly assigned to one of two groups: one group will take the bacterial supplement by mouth twice daily for 3 or 6 weeks of each cycle, plus receive the immunotherapy drug by IV infusion on day 1 of each cycle; the other group will receive only the immunotherapy drug by IV infusion. Both groups will repeat this cycle every 3 or 6 weeks for up to 12 months. Throughout the study, you'll have regular blood draws and CT scans to check your health and whether the cancer has returned. After you finish treatment, you'll have one follow-up visit 30 days later.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Adding a gut bacteria treatment to cancer immunotherapy after kidney surgery

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)